

CME Activity: The Role of Iron Chelation Therapy for Patients With Myelodysplastic Syndromes

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions and earn continuing medical education (CME) credit, please go to www.medscapecme.com/journal/jnccn.

Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on Medscape.com. If you are not registered on Medscape.com, please click on the New Users: Free Registration link on the left hand side of the website to register.

Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions re-

garding the content of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@webmd.net.

American Medical Association's Physician's Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to <http://www.ama-assn.org/ama/pub/category/2922.html>. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit is acceptable as evidence of participation in CME activities. If you are not licensed in the U.S. and want to obtain an AMA PRA CME credit, please complete the questions online, print the certificate and present it to your national medical association.

- You are seeing a 65-year-old woman with myelodysplastic syndrome (MDS) and chronic anemia. She has received 5 red blood cell (RBC) transfusions in the past 3 years. She wants to know more about anemia and its treatment in the context of MDS. What can you tell her?
 - Most patients with MDS do not have anemia at the time of diagnosis
 - The need for RBC transfusions does not have an impact on the prognosis of MDS
 - The specific reasons for interactions between RBC transfusions and MDS are not clear
 - High serum ferritin levels predict lower mortality in MDS
- What should you consider regarding hemosiderosis and MDS in this patient?
 - Serum transferrin saturation is the best means to measure the degree of iron overload
 - Iron overload probably does not affect the status of stem cell transplant recipients
 - Cardiac iron accumulation is ubiquitous among patients with hemosiderosis
 - Iron overload probably does not affect the status of patients with MDS who have excess sideroblasts or a complex karyotype
- Laboratory testing reveals iron overload in this patient. Which of the following outcomes can be expected from the initiation of iron chelation therapy (ICT)?
 - No change in serum ferritin or labile plasma iron (LPI) levels
 - Improvement in serum ferritin but not LPI levels
 - Improvement in LPI but not serum ferritin levels
 - Improvement in both serum ferritin and LPI levels
- You consider initiating ICT with deferasirox in this patient. Which of the following adverse events is most common with this form of ICT?
 - Gastrointestinal side effects
 - Rash
 - Renal insufficiency
 - Fungal infection

Activity Evaluation

- | | |
|---|---|
| <p>1. The activity supported the learning objectives.</p> <p>Strongly Disagree Strongly Agree</p> <p>1 2 3 4 5</p> | <p>3. The content learned from this activity will impact my practice.</p> <p>Strongly Disagree Strongly Agree</p> <p>1 2 3 4 5</p> |
| <p>2. The material was organized clearly for learning to occur.</p> <p>Strongly Disagree Strongly Agree</p> <p>1 2 3 4 5</p> | <p>4. The activity was presented objectively and free of commercial bias.</p> <p>Strongly Disagree Strongly Agree</p> <p>1 2 3 4 5</p> |

To obtain credit, visit Medscape online at <http://www.medscapecme.com/journal/jnccn>.